Australian Clinical Labs (ASX:ACL) Debt-to-Equity : 1.87 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Debt-to-Equity?

Australian Clinical Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$110.7 Mil. Australian Clinical Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$204.6 Mil. Australian Clinical Labs's Total Stockholders Equity for the quarter that ended in Dec. 2024 was A$168.7 Mil. Australian Clinical Labs's debt to equity for the quarter that ended in Dec. 2024 was 1.87.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Australian Clinical Labs's Debt-to-Equity or its related term are showing as below:

ASX:ACL' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.13 Med: 1.85 Max: 5.59
Current: 1.87

During the past 5 years, the highest Debt-to-Equity Ratio of Australian Clinical Labs was 5.59. The lowest was 1.13. And the median was 1.85.

ASX:ACL's Debt-to-Equity is ranked worse than
93.48% of 184 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.29 vs ASX:ACL: 1.87

Australian Clinical Labs Debt-to-Equity Historical Data

The historical data trend for Australian Clinical Labs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Debt-to-Equity Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

5.59

3.59

1.13

1.84

1.74

Australian Clinical Labs Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial				1.85	1.84	1.98	1.74	1.87

Competitive Comparison of Australian Clinical Labs's Debt-to-Equity

For the Diagnostics & Research subindustry, Australian Clinical Labs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Australian Clinical Labs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Australian Clinical Labs's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(104.709	+	204.19)	/	177.528
	=	1.74

Australian Clinical Labs's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(110.697	+	204.622)	/	168.721
	=	1.87

Australian Clinical Labs (ASX:ACL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Australian Clinical Labs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines